How can pharmaceutical manufacturers best ensure the accuracy of the product they’re filling and the integrity of a batch run? Strategies are typically identified based on the scope of the operation, batch size, and the properties of the product itself.
A crucial aspect of those strategies is in-process weight checks (IPC), which utilise weigh cells to provide feedback on the dispensing accuracy of the pump.
In the world of fill-finish, ensuring that this aspect of analytical technology is executed effectively and efficiently is pivotal for sustained production.
For high-value liquid pharmaceuticals, it’s common for 100 percent IPC to be run to ensure quality. The continued rise of ATMPs spotlights the need for innovative approaches to end-to-end product stewardship. Highly targeted, patient-centered treatments simply can’t be wasted at any stage of the fill-finish process.
AST set out to explore what the next advancement in this important process could look like. What if manufacturers could run their aseptic machine in end-of-batch mode, using every possible drop of the product with no compromise to output speed? What if operations were equipped with the capabilities to run a 100 percent IPC rate in a fraction of the time when compared to current methods?
In this white paper, Vice President of Technical Sales Josh Russell dives into AST’s latest process advancement, Augmented IPC, chronicles the rise of patient-centered medicine, and examines the crucial roles that quality measures like IPC will play in the future of liquid pharmaceuticals.
Download AST’s Latest White Paper